Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

被引：0
|
作者：
Lucien Marchand
Sophie Reffet
Stéphane Dalle
Emmanuel Disse
Julien Vouillarmet
Christine Cugnet-Anceau
Charles Thivolet
机构：
[1] Hospices Civils de Lyon,Department of Endocrinology and Diabetes
[2] Lyon-Sud Hospital,Department of Dermatology
[3] Hospices Civils de Lyon,ImmuCare (Immunology Cancer Research)
[4] Lyon-Sud Hospital,undefined
[5] Hospices Civils de Lyon,undefined
[6] Lyon 1 University,undefined
[7] CarMeN Laboratory (INSERM U1060,undefined
[8] INRA U1235,undefined
[9] Université Claude Bernard Lyon1,undefined
[10] INSA-Lyon),undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Diabetes mellitus; Fulminant diabetes; Glucose variability; Coefficient of variation for glucose; Labile diabetes; Flash glucose monitoring; FreeStyle Libre; Autoimmune diabetes; Immune checkpoint inhibitors side effects; Immunotherapy; Programmed cell death-1; Anti-PD-1; Programmed death ligand 1; Anti-PD-L1; Beta-cell pancreatic function; Alpha-cell pancreatic function; Exocrine pancreatic function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：377 / 378
页数：1
相关论文
共 50 条
  • [1] Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
    Marchand, Lucien
    Reffet, Sophie
    Dalle, Stephane
    Disse, Emmanuel
    Vouillarmet, Julien
    Cugnet-Anceau, Christine
    Thivolet, Charles
    ACTA DIABETOLOGICA, 2019, 56 (03) : 377 - 378
  • [2] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [3] Glucose variability in PD-1 inhibitors-induced diabetes mellitus
    Francesco Tassone
    Elena Gamarra
    Acta Diabetologica, 2019, 56 : 379 - 380
  • [4] Glucose variability in PD-1 inhibitors-induced diabetes mellitus
    Tassone, Francesco
    Gamarra, Elena
    ACTA DIABETOLOGICA, 2019, 56 (03) : 379 - 380
  • [5] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [6] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
    Marchand, Lucien
    Thivolet, Arnaud
    Dalle, Stephane
    Chikh, Karim
    Reffet, Sophie
    Vouillarmet, Julien
    Fabien, Nicole
    Cugnet-Anceau, Christine
    Thivolet, Charles
    ACTA DIABETOLOGICA, 2019, 56 (04) : 441 - 448
  • [8] Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash
    Hirata, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
    Lucien Marchand
    Arnaud Thivolet
    Stéphane Dalle
    Karim Chikh
    Sophie Reffet
    Julien Vouillarmet
    Nicole Fabien
    Christine Cugnet-Anceau
    Charles Thivolet
    Acta Diabetologica, 2019, 56 : 441 - 448
  • [10] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
12345